Portfolio News

Golgi Neurosciences announces Breye Therapeutics to start Phase 1b/2a clinical trials Milan (Italy) – Golgi Neurosciences Srl is thrilled to share an update from its portfolio company Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology. Breye Therapeutics has initiated phase 1b/2a clinical trial, with the scope … Read more

Lario Therapeutics Limited, a biopharmaceutical company developing first-in-class precision medicines targeting disease-modifying treatments for severe neurological disorders.

Acousia Therapeutics GmbH, a clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss.